科拓生物(300858.SZ):就申請定增、收到審核問詢函
格隆匯8月15日丨科拓生物(300858.SZ)公佈,公司於2022年8月15日收到深圳證券交易所(“深交所”)出具的《關於北京科拓恆通生物技術股份有限公司申請向特定對象發行股票的審核問詢函》(審核函﹝2022﹞020188號),深交所上市審核中心對公司向特定對象發行股票的申請文件進行了審核,並形成了審核問詢問題。
公司將按照審核問詢函的要求,與相關中介機構逐項落實並及時提交對審核問詢函的回覆,回覆的內容將通過臨時公吿方式披露,並在披露後通過深交所發行上市審核業務系統報送相關文件。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.